

CIF A-18.758.300
Avda de la Innovación, n 1
Edificio BIC (Ofic 211)
P. T. de Ciencias de la Salud
18100 Armilla (Granada)
Tel: 958 750 598

Mercado Alternativo Bursátil
Plaza de la Lealtad, 1
28014 Madrid

In Granada, 10 June 2014

RELEVANT FACT OF NEURON BIOPHARMA, S.A.

Dear Sirs,

In compliance with the provisions of the MAB circular 9/2010 on information to be provided by the companies in expansion integrated in the MAB, Neuron Biopharma S.A. (hereinafter "NEURON BIO" or the "Company") hereby informs that:

The Spanish Patent and Trademarks office (OEPM) has granted Neuron Bio with the patent "Formyl analogues of xantocilines as neuroprotectors" published in the Spanish Official Bulletin of Industrial Property with number ES2418684B1.

The patent protects the use of a compound family derived from xantociline, among which is the molecule known under the Neuron Bio working code NPS0163, a potential treatment for neurodegenerative disease and particularly for the treatment of the Alzheimer's disease. The compound NPS0163, which is part of the company portfolio, has a high neuroprotective capacity and a structure never described to date.

We remain at your disposal for any clarification you consider appropriate.

Kind regards,

Fernando Valdivieso Amate
Chairman of the Board of Directors